GRAL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Grail Inc (GRAL) is not a strong buy at this moment for a beginner investor with a long-term focus. Despite some positive catalysts, the recent clinical trial failure, declining financial metrics, and mixed analyst sentiment suggest holding off on investment until clearer growth signals emerge.
The MACD is negative and contracting, RSI is neutral at 33.703, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 49.37) but far from its pivot (75.172), suggesting limited immediate upside.
Baker Bros. Advisors purchased 455,208 shares, signaling confidence in the company's future.
Revenue increased by 13.97% YoY in Q4
Grail remains a dominant player in the $70B multi-cancer early detection market.
The NHS-Galleri trial failed to meet its primary endpoint, leading to a 50% stock drop.
Gross margin dropped significantly (-38.81% YoY), and EPS declined (-15.57% YoY).
Analysts have lowered price targets, reflecting uncertainty about reimbursement and future growth.
In Q4 2025, revenue grew by 13.97% YoY to $43.6M, but net income remained negative at -$99.18M (up 2.17% YoY). EPS dropped to -2.44 (-15.57% YoY), and gross margin deteriorated to -25.54% (-38.81% YoY), indicating financial challenges.
Analysts are mixed: Morgan Stanley lowered the price target to $60 with an Equal Weight rating, while Canaccord and Baird remain optimistic with Buy/Outperform ratings despite reducing price targets. TD Cowen initiated coverage with a Hold rating, citing risks despite Grail's market dominance.
